Good morning :)
Place Order
Add to Watchlist

Glenmark Pharmaceuticals Ltd

GLENMARK Share Price

1,368.801.97% (+26.40)

GLENMARK Share Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹38,627 cr, stock is ranked 212
Moderate RiskStock is 2.05x as volatile as Nifty

GLENMARK Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹38,627 cr, stock is ranked 212
Moderate RiskStock is 2.05x as volatile as Nifty

GLENMARK Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-219.704.920.18%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.796.340.53%

GLENMARK Analyst Ratings & Forecast

Detailed Forecast 
82%
Analysts have suggested that investors can buy this stock

from 11 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

GLENMARK Company Profile

Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

Investor Presentation

View older 

Feb 14, 2025

PDF
View Older Presentations

GLENMARK Similar Stocks (Peers)

Compare with peers 
PE Ratio
43.72
1Y Return
13.30%
Buy Reco %
88.24
PE Ratio
29.61
1Y Return
11.53%
Buy Reco %
72.73
PE Ratio
66.50
1Y Return
25.57%
Buy Reco %
68.00
PE Ratio
55.83
1Y Return
10.60%
Buy Reco %
81.25
PE Ratio
17.56
1Y Return
2.15%
Buy Reco %
46.67
Compare with Peers

GLENMARK Forecasts

Price

Revenue

Earnings

GLENMARK

Income

Balance Sheet

Cash Flow

GLENMARK Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 4.97%, vs industry avg of 9.04%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 4.66% to 3.42%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue7,581.679,116.789,165.8210,240.7910,833.4511,038.6912,471.5712,339.1013,050.4214,028.06
Raw Materialssubtract2,442.743,073.932,904.863,421.013,570.563,809.434,396.424,498.194,608.9911,280.56
Power & Fuel Costsubtract120.47127.02137.48165.26173.69164.67200.64111.75124.00
Employee Costsubtract1,378.201,640.811,871.842,056.072,254.782,343.712,447.422,600.782,868.14
Selling & Administrative Expensessubtract1,395.791,589.861,523.271,750.211,667.021,453.551,543.271,752.301,708.60
Operating & Other expensessubtract787.32692.041,021.60887.121,276.841,088.191,657.761,751.062,208.99
Depreciation/Amortizationsubtract234.28264.37301.88325.91417.17443.55486.72569.17581.91512.15
Interest & Other Itemssubtract178.89237.32285.57334.59377.32353.11298.10349.04515.97288.91
Taxes & Other Itemssubtract300.94382.67315.46375.63320.11412.44499.54409.561,935.492,122.26
EPS26.8539.2928.4932.7827.5034.3833.3710.53-53.22-6.23
DPS2.002.002.002.002.502.502.502.502.502.50
Payout ratio0.070.050.070.060.090.070.070.24-0.40

GLENMARK Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2015

Annual report

PDF

Investor Presentation

Jan 14PDF
FY 2016

Annual report

PDF

Investor Presentation

Jan 12PDF
FY 2017

Annual report

PDF

Investor Presentation

Jul 19PDF
FY 2023

Annual report

PDF

Investor Presentation

May 19PDF
Feb 10PDF
Nov 17PDF
FY 2024

Annual report

PDF

Investor Presentation

Sep 21PDF
Aug 11PDF
FY 2025

Annual Report Pending

Investor Presentation

Feb 14PDF
Nov 14PDF
 

GLENMARK Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Glenmark Pharmaceuticals Ltd-25.724.920.18%
Sun Pharmaceutical Industries Ltd43.726.240.77%
Cipla Ltd29.614.550.86%
Torrent Pharmaceuticals Ltd66.5016.070.86%

GLENMARK Stock Price Comparison

Compare GLENMARK with any stock or ETF
Compare GLENMARK with any stock or ETF
GLENMARK
Loading...

GLENMARK Shareholdings

GLENMARK Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

GLENMARK Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

GLENMARK Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding46.65%12.86%1.74%23.16%15.59%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

GLENMARK Shareholding History

Dec '23MarJunSepDec '24Mar23.71%21.38%20.98%23.05%23.51%23.16%

Mutual Funds Invested in GLENMARK

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Glenmark Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
3.5711%1.86%0.24%9/85 (0)
1.3477%1.40%0.01%61/115 (0)
0.9710%1.64%0.11%52/100 (-1)

Compare 3-month MF holding change on Screener

GLENMARK Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing GLENMARK stock

Looks like this stock is not in any smallcase yet.

GLENMARK Events

GLENMARK Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

GLENMARK has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.19%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.86 every year

Dividends

Corp. Actions

Announcements

Legal Orders

GLENMARK Upcoming Dividends

No upcoming dividends are available

GLENMARK Past Dividends

Cash Dividend

Ex DateEx DateSep 13, 2024

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 13, 2024

Cash Dividend

Ex DateEx DateSep 18, 2023

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 18, 2023

Cash Dividend

Ex DateEx DateSep 12, 2022

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 12, 2022

Cash Dividend

Ex DateEx DateSep 8, 2021

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 8, 2021

Cash Dividend

Ex DateEx DateSep 17, 2020

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 17, 2020

GLENMARK Stock News & Opinions

Corporate
Glenmark Pharmaceuticals allots 12,653 equity shares under ESOP

Glenmark Pharmaceuticals has allotted 12,653 equity shares under ESOP. Consequently, the paid up equity share capital has increased 28,22,00,809 equity shares of Re. 1 each aggregating to Rs. 28,22,00,809/-. Powered by Capital Market - Live

4 days agoCapital Market - Live
Spotlight
Glenmark Pharma's US arm set to launch generic Adderall tablets

The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (mixed salts of a single entity Amphetamine product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Glenmark's product is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall Tablets (5 mg to 30 mg), marketed by Teva Women's Health, Inc. Distribution is scheduled to begin in May 2025. According to IQVIA, sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million. Commenting on the launch, Marc Kikuchi, president with a focus on therapeutic areas of cardiometabolic, respiratory, dermatology and oncology Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of cardiometabolic, respiratory, dermatology and oncology. The company reported a consolidated net profit of Rs 347.96 crore in Q3 FY25 as compared with net loss of Rs 351.37 crore in Q3 FY24. Net sales increased 34.2% YoY to Rs 3,301.90 crore in Q3 FY25. The counter declined 1.34% to settle at Rs 1,356.95 on Wednesday, 17 April 2025.Powered by Capital Market - Live

4 days agoCapital Market - Live
Corporate
Glenmark USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall'2 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc. and the company will begin distribution in May 2025. According to IQVIA sales data for the 12-month period ending February 2025, the Adderall' Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million. Powered by Capital Market - Live

5 days agoCapital Market - Live
Spotlight
Glenmark Pharmaceuticals Ltd slips for fifth straight session

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1371.95, down 0.32% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 2.16% on the day, quoting at 22882.3. The Sensex is at 75328, up 2.01%.Glenmark Pharmaceuticals Ltd has lost around 3.54% in last one month.Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has increased around 0.27% in last one month and is currently quoting at 19976.3, up 2.51% on the day. The volume in the stock stood at 4.59 lakh shares today, compared to the daily average of 6.56 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 1376.9, up 0.02% on the day. Glenmark Pharmaceuticals Ltd jumped 30.44% in last one year as compared to a 1.61% rally in NIFTY and a 9% spurt in the Nifty Pharma index.The PE of the stock is 16.86 based on TTM earnings ending December 24.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Glenmark Pharmaceuticals announces change in senior management

Glenmark Pharmaceuticals has appointed Anurag Mantri as President (Senior Management Personnel) with effect from 07 April 2025. Further, V.S. Mani, Executive Director & Global Chief Financial Officer of the Company has decided to step down with effect from 26 May 2025. The candidature of Anurag Mantri to the office of Executive Director & Global Chief Financial Officer will be put up before Audit Committee, Nomination & Remuneration Committee and Board of the Company in the ensuing committee meetings/Board meeting for approval and once approved, he will then be appointed as Executive Director and Global Chief Financial Officer. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Glenmark launches Vancomycin Hydrochloride for injection USP in the USA

Vancomycin injection is used alone or in combination with other medications to treat certain serious infections, such as endocarditis (infection of the heart lining and valves), peritonitis (inflammation of the lining of the abdomen), and infections of the lungs, skin, blood, and bones. It belongs to a class of medications called glycopeptide antibiotics and works by killing the bacteria that cause infections. Glenmark's Vancomycin Hydrochloride for Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, marketed by Mylan Laboratories. According to IQVIA' sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP market achieved annual sales of approximately $39.3 million. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024. The scrip shed 0.58% to Rs 1,531.05 on the BSE Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Glenmark Pharmaceuticals launches Vancomycin Hydrochloride for Injection USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories, NDA 209481. According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market2 achieved annual sales of approximately $39.3 million. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Glenmark Pharma gains as arm gets USFDA nod for Olopatadine Ophthalmic solution

The product has been determined to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), developed by Alcon Laboratories, Inc. With this approval, Glenmark Therapeutics Inc., USA, will distribute the product in the US market, further expanding the company's ophthalmic portfolio. Olopatadine ophthalmic (eye) drops are used to treat itching of the eye caused by a condition known as allergic conjunctivitis (pink eye). This medicine is also used to treat eye itching or redness caused by pollen, ragweed, grass, animal hair, or dander. According to Nielsen syndicated data for the 52-week period ending 22 February 2025, the Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), achieved annual sales of approximately $50.7 million. Commenting on the launch, Marc Kikuchi, president & business head of North America, said, 'We are pleased to continue expanding our OTC ophthalmic portfolio. The addition of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%, highlights our commitment to meeting market needs and providing quality over-the-counter solutions for our customers.' Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Glenmark Pharmaceuticals launches Empagliflozin in India

Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk.  Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Glenmark Pharma launches generic Empagliflozin in India

The drug will be marketed under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). Empagliflozin is a globally established treatment for heart failure and diabetes, offering multiple benefits, including cardiovascular and renal safety. Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals, said, 'Glenmark has a strong legacy of introducing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.' Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024. The scrip fell 1.38% to currently trade at Rs 1,381.15 on the BSE.Powered by Capital Market - Live

1 month agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Glenmark Pharmaceuticals Ltd (GLENMARK) today?

    The share price of GLENMARK as on 21st April 2025 is ₹1368.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Glenmark Pharmaceuticals Ltd (GLENMARK) share?

    The past returns of Glenmark Pharmaceuticals Ltd (GLENMARK) share are
    • Past 1 week: -2.87%
    • Past 1 month: -10.26%
    • Past 3 months: -8.72%
    • Past 6 months: -20.27%
    • Past 1 year: 31.70%
    • Past 3 years: 201.76%
    • Past 5 years: 333.99%

  3. What are the peers or stocks similar to Glenmark Pharmaceuticals Ltd (GLENMARK)?
  4. What is the dividend yield % of Glenmark Pharmaceuticals Ltd (GLENMARK) share?

    The current dividend yield of Glenmark Pharmaceuticals Ltd (GLENMARK) is 0.18.

  5. What is the market cap of Glenmark Pharmaceuticals Ltd (GLENMARK) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹38627.65 Cr as of 21st April 2025.

  6. What is the 52 week high and low of Glenmark Pharmaceuticals Ltd (GLENMARK) share?

    The 52-week high of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹1830.95 and the 52-week low is ₹985.20.

  7. What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd (GLENMARK) stock?

    The P/E (price-to-earnings) ratio of Glenmark Pharmaceuticals Ltd (GLENMARK) is -25.72. The P/B (price-to-book) ratio is 4.92.

  8. Which sector does Glenmark Pharmaceuticals Ltd (GLENMARK) belong to?

    Glenmark Pharmaceuticals Ltd (GLENMARK) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Glenmark Pharmaceuticals Ltd (GLENMARK) shares?

    You can directly buy Glenmark Pharmaceuticals Ltd (GLENMARK) shares on Tickertape. Simply sign up, connect your demat account and place your order.